{
    "root": "e4c4122b-6772-46a0-aaaa-3815e6a9736f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Atomoxetine",
    "value": "20250326",
    "ingredients": [
        {
            "name": "ATOMOXETINE HYDROCHLORIDE",
            "code": "57WVB6I2W0"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "DIMETHICONE, UNSPECIFIED",
            "code": "92RU3N3Y1O"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        }
    ],
    "indications": "atomoxetine hydrochloride selective norepinephrine reuptake inhibitor indicated treatment attention-deficit/hyperactivity disorder ( adhd ) . ( 1.1 )",
    "contraindications": "initial , target maximum daily dose ( 2.1 ) ( acute maintenance/extended treatment ) body weight initial daily dose target total daily dose maximum daily dose total children adolescents 70 kg 0.5 mg/kg 1.2 mg/kg 1.4 mg/kg children adolescents 70 kg adults 40 mg 80 mg 100 mg dosing adjustment – hepatic impairment , strong cyp2d6 inhibitor , patients known cyp2d6 poor metabolizers ( pms ) . ( 2.5 , 12.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "• hypersensitivity atomoxetine constituents product . ( 4.1 ) • atomoxetine hydrochloride within 2 weeks discontinuing maoi drugs affect brain monoamine concentrations . ( 4.2 , 7.1 ) • narrow angle glaucoma . ( 4.3 ) • pheochromocytoma history pheochromocytoma . ( 4.4 ) • severe cardiovascular disorders might deteriorate clinically important increases hr bp . ( 4.5 )",
    "indications_original": "Atomoxetine hydrochloride is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). (1.1)",
    "contraindications_original": "Initial, Target and Maximum Daily Dose (2.1) (Acute and Maintenance/Extended Treatment) Body Weight Initial Daily Dose Target Total Daily Dose Maximum Daily Dose Total Children and adolescents up to 70 kg 0.5 mg/kg 1.2 mg/kg 1.4 mg/kg Children and adolescents over 70 kg and adults 40 mg 80 mg 100 mg Dosing adjustment – Hepatic Impairment, Strong CYP2D6 Inhibitor, and in patients known to be CYP2D6 poor metabolizers (PMs). ( 2.5 , 12.3 )",
    "adverseReactions_original": "• Hypersensitivity to atomoxetine or other constituents of product. (4.1) • Atomoxetine hydrochloride use within 2 weeks after discontinuing MAOI or other drugs that affect brain monoamine concentrations. ( 4.2 , 7.1 ) • Narrow Angle Glaucoma. (4.3) • Pheochromocytoma or history of pheochromocytoma. (4.4) • Severe Cardiovascular Disorders that might deteriorate with clinically important increases in HR and BP. (4.5)"
}